Opko健康 OPK 深 沪
等待开盘 02-07 09:30:00 美东时间
1.24
+0.010
+0.81%
华盛通- 最 高1.25
- 今 开1.24
- 成交量 264.57万股
- 最 低 1.23
- 昨 收 1.23
- 总市值 9.52亿
- 52周最高 2.035
- 市盈率 静 --
- 换手率 0.34%
- 52周最低 1.11
- 委 比 25.30%
- 总股本 7.68亿
- 历史最高 19.20
- 量 比 0.70
- 振 幅 1.63%
- 历史最低 0.8516
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OPKO Health Expands Partnership With Entera Bio To Advance First-in-Class Oral Long Acting PTH Tablet
This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilitiesThe companies have accelerated this program and aim to file an
02-04 21:05
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Entera Bio Ltd. announced its key milestones for Q1 2026, including submitting the final Phase 3 protocol for EB613 to the FDA, expecting results from the Next-Generation EB613 Phase 1 bridging study, accelerating its hypoparathyroidism program with long-acting PTH variants, and advancing strategic partnerships across its pipeline. The Company remains committed to addressing unmet medical needs in osteoporosis and hypoparathyroidism.
01-21 13:30
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. Management will host investor meetings and engage in a fireside chat on January 14 at 1:30 p.m. PT, available live and on replay via the company’s website. OPKO is a biopharmaceutical and diagnostics company focusing on large, rapidly growing markets. For more details, visit their website or contact Allia...
01-06 21:11
JP Morgan Initiates Coverage On OPKO Health with Neutral Rating
JP Morgan analyst Brian Cheng initiates coverage on OPKO Health (NASDAQ:OPK) with a Neutral rating.
2025-11-20 19:47
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
OPKO Health announced its participation in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York City. OPKO management will engage in one-on-one meetings with investors and a fireside discussion on December 3rd at 12:00 p.m. Eastern time. Investors can contact their Piper Sandler representative to schedule meetings. OPKO is a multinational biopharmaceutical and diagnostics company focusing on large, rapidly grow...
2025-11-19 21:05
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
2025-11-03 20:20
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
<p>ModeX Therapeutics and Regeneron Pharmaceuticals have entered into a collaboration to develop multispecific antibodies targeting multiple disease pathways. ModeX will receive USD $7 million upfront, plus potential milestone and royalty payments exceeding USD $200 million per molecule, with a potential total value over $1 billion. The MSTAR platform will be used to create innovative antibody candidates for indications like immunology, oncology,...
2025-10-29 12:00
OPKO Health Q3 Earnings Preview
OPKO Health (NASDAQ:OPK) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is -$0.04 and the consensus revenue estimate is $165.74...
2025-10-29 05:35
An OPKO Health's Modex Therapeutics Company Doses First Patient In Its Phase 1/2a Trial Of MDX2004, A First-In-Class Trispecific Antibody-fusion Protein For Advanced Cancers
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 ModeX Therapeutics
2025-10-28 20:08
